Comparative Pharmacology
Head-to-head clinical analysis: COXANTO versus MECLOFENAMATE SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COXANTO versus MECLOFENAMATE SODIUM.
COXANTO vs MECLOFENAMATE SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of soluble epoxide hydrolase (sEH), increasing levels of epoxyeicosatrienoic acids (EETs), which have vasodilatory, anti-inflammatory, and antifibrotic effects.
Meclofenamate sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
1 g intravenous every 6 hours.
50 mg or 100 mg orally three times daily; maximum 400 mg/day.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours (prolonged to 24-30 hours in moderate-to-severe renal impairment, requiring dose adjustment)
2-4 hours (terminal half-life; may be prolonged in hepatic impairment or elderly)
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Renal (60-70% as metabolites and conjugates), biliary/fecal (20-30%)
Category C
Category C
NSAID
NSAID